Introduction {#Sec1}
============

Irritable bowel syndrome (IBS) is a gastrointestinal chronic disorder which is characterized by abdominal discomfort or pain associated with altered bowel habits, and often bloating and abdominal distension \[[@CR1], [@CR2]\]. The degree of symptoms varies in different patients from tolerable to severe, with a considerable reduction of quality of life and productivity \[[@CR1]--[@CR5]\]. This disorder affects 10--15% of the western population with female predominance \[[@CR1], [@CR2]\]. Besides the increased morbidity caused by IBS, it is an economic burden to society in different indirect forms, for example increased sick leave and over-consumption of healthcare resources \[[@CR6], [@CR7]\].

Disturbances of gastrointestinal motility have been reported in patients with IBS \[[@CR8]--[@CR14]\]. It has been speculated that this dysmotility is caused by genetic and psychosocial factors, and stress \[[@CR6], [@CR7]\]. The gastrointestinal tract hormones are important in regulating gastrointestinal motility \[[@CR15]\]. Few studies have been conducted on gut hormones in IBS patients \[[@CR16]--[@CR23]\]. These studies concentrated mostly on serotonin \[[@CR16]--[@CR19]\].

In a previous study, the density of chromogranin A was reduced in the colon of patients with IBS \[[@CR24]\]. Chromogranin A is a general marker for all endocrine cells. This finding raises the question as to which endocrine cell type is affected in the colon. Thus, this study was undertaken to discover the endocrine cell type(s) affected in the colon of IBS patients.

Materials and Methods {#Sec2}
=====================

Patients and Controls {#Sec3}
---------------------

Forty-one patients with irritable bowel syndrome that fulfilled Rome Criteria III using the IBS module were included in the study \[[@CR25], [@CR26]\]. These patients were 39 females and two males with an average age of 35 years (range 18--58 years). Twenty-three patients had diarrhea (IBS-diarrhea) and 18 patients had constipation (IBS-constipation) as the predominant symptom. All patients underwent a complete physical examination and were investigated by means of blood tests (full blood count, electrolytes, calcium, and inflammatory markers), liver tests, and thyroid function tests.

Twenty subjects that underwent colonoscopy with biopsies were used as controls. Twelve of these subjects underwent colonoscopy because of gastrointestinal bleeding, where the source of bleeding was identified as hemorrhoids, and eight subjects because of health worries caused by a relative(s) having been diagnosed with colon carcinoma. These subjects were 13 females and seven males with an average age of 49 years (range 24--66 years).

The study was performed in accordance with the Declaration of Helsinki and was approved by the local Committee for Medical Research Ethics. All subjects gave oral and written consent.

Colonoscopy {#Sec4}
-----------

Colonoscopy was performed on patients and controls, and two biopsies were taken from the cecum, from the ascending colon, and from the right half of the transverse colon. All six biopsies were pooled and used as the right colon. Moreover, two biopsies were taken from the left half of the transverse colon, from the descending colon, and from the sigmoid colon. These six biopsies were pooled and used as the left colon.

Histopathology and Immunohistochemistry {#Sec5}
---------------------------------------

Biopsies were fixed overnight in 4% buffered paraformaldehyde, embedded in paraffin, and cut into 5-μm sections. The sections were stained with hematoxylin--eosin and immunostained by use of the avidin--biotin complex (ABC) method using the Vectastain ABC kit (Vector Laboratories) as described in detail elsewhere \[[@CR27]\]. The primary antibodies used were: monoclonal mouse anti-serotonin (DakoCytomation, code no. 5HT-209), polyclonal anti-porcine peptide YY (PYY; Alpha-diagnostica, code PYY 11A), polyclonal rabbit anti-synthetic human pancreatic polypeptide (PP; Diagnostic Biosystems, code no. \#114), polyclonal rabbit anti-porcine glicentin/glucagon (Acris Antibodies, code BP508), and polyclonal rabbit anti-synthetic human somatostatin (DakoCytomation, code no. A566). The antibodies were used at dilutions of 1:1,500, 1:1,000, 1:800, 1:400, and 1:200, respectively. The second layer biotinylated mouse anti-IgG and rabbit anti-IgG were obtained from DakoCytomation. Negative and positive controls were the same as those described elsewhere \[[@CR27]\]. Anti-PYY cross-reacted \<0.001% with neuropeptide Y (NPY) in the radioimmunoassay system.

Computerized Image Analysis {#Sec6}
---------------------------

Numbers of immunoreactive cells and areas of the epithelial cells were measured by use of the Olympus software: Cell\^D. The ×40 objective was used, so the frame (field) on the monitor represented an area of 0.14 mm^2^ of the tissue in each field. Each individual and peptide hormone was measured in 10 randomly chosen fields. Immunostained sections from IBS patients and controls were coded and mixed, and measurements were made without knowledge of the identity of the sections. The data from the fields were tabulated; the number of cells/mm^2^ of the epithelium was computed and statistically analyzed automatically.

Statistical Analysis {#Sec7}
--------------------

The Kruskal--Wallis non-parametric ANOVA test and Dunn\`s post-test were used. *P* values \<0.05 were considered significant.

Results {#Sec8}
=======

Endoscopy, Histopathology, and Immunohistochemistry {#Sec9}
---------------------------------------------------

The colons of patients and control subjects were macroscopically normal.

Histopathological examination of the colon biopsies from patients and controls revealed normal histology, except for four controls and five patients, where nonspecific inflammation was found. In the colon of patients and control subjects, serotonin, PYY, PP, entroglucagon, and somatostatin-immunoreactive cells were found, mostly in the upper part of the crypts of Lieberkühn. These cells were basket or flask-shaped (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}).Fig. 1Serotonin-immunoreactive cells in the colon of a healthy volunteer (**a**) and of a patient with IBS (**b**)Fig. 2PYY-immunoreactive cells in the colon of a healthy volunteer (**a**) and of a patient with IBS-diarrhea (**b**)

Computerized Image Analysis {#Sec10}
---------------------------

PP, entroglucagon, and somatostatin-immunoreactive cells were too few in the biopsy material examined. This made it difficult to quantify these cell types reliably.

There was no statistically significant difference between the right and left colon in controls regarding densities of serotonin and PYY-immunoreactive cells (*P* = 0.9 and 0.1, respectively).

Serotonin cell density was reduced in the colon of IBS patients (Figs. [1](#Fig1){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). This reduction was found in both IBS-diarrhea and IBS-constipation patients. In the right colon, serotonin cell density in IBS patients as a whole and in both sub-types was lower than in controls (Fig. [3](#Fig3){ref-type="fig"}). In the left colon, serotonin cell density was reduced in IBS patients as a whole and in IBS-diarrhea patients, but not in those with IBS-constipation (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Density of serotonin cells in the colon in IBS patients and as a whole and in the two subtypes of IBS (**a**), in the right colon (**b**), and in the left colon (**c**). Statistical significance expressed as comparison between controls and IBS patients and subtypes. \*\**P* \< 0.01 and \*\*\**P* \< 0.001

PYY cell density was lower than controls in the colon as a whole and in the right and left colon. PYY cell density was reduced also in both sub-types of IBS (Figs. [2](#Fig2){ref-type="fig"}, [4](#Fig4){ref-type="fig"}).Fig. 4PYY cell density in the colon in IBS patients and as a whole and in the two subtypes of IBS (**a**), in the right colon (**b**), and in the left colon (**c**). Statistical significance expressed as in Fig. [3](#Fig3){ref-type="fig"}

Discussion {#Sec11}
==========

The age and sex of the patients and control subjects used in this investigation did not match completely. The control subjects are slightly older and the proportion of males to females is higher. In previous studies, however, age and gender have been found to have no effect on the density of intestinal endocrine cells in adults \[[@CR28], [@CR29]\]. Different topographic distribution of large intestinal endocrine cell densities has previously been reported \[[@CR30]\]. Thus, in this investigation endocrine cell densities were studied in different segments of the colon.

This study showed that serotonin and PYY cell densities were reduced in both sub-types of IBS, i.e. IBS-diarrhea and IBS-constipation. It is noteworthy, however, that in the left colon of patients with IBS-constipation, serotonin cell density was not statistically significant. One cannot exclude the possibility this was a type II statistical error; however, in a previous report chromogranin A cell density was also not significant in the same segment of the colon of the same patient group \[[@CR24]\]. Mucosal 5-HT concentration has been reported to be low in IBS patients \[[@CR31]\], in agreement with our observation. Previous studies of patients with post-infectious IBS (PI-IBS) of the diarrhea-predominant type have shown however, that the number of serotonin cells increased in the rectum \[[@CR16], [@CR19], [@CR32], [@CR33]\]. Our finding that serotonin cell density was reduced in the colon raises the possibility that PI-IBS and sporadic IBS can have a different pathophysiology. One should also point out that the rectum harbors a larger number of endocrine cells than the colon \[[@CR30]\].

The low densities of serotonin and PYY cells in IBS patients found here could be primary or secondary to other pathological process. Thus, the cause of these observations could be primary genetic defect(s), secondary to altered serotonin and/or PYY signaling systems and/or subclinical inflammation. It is not known whether a defect occurs in the genes controlling the expression of serotonin and PYY. However, an association between a functional polymorphism in the serotonin transporter (SERT) gene and diarrhea-predominant IBS has been reported \[[@CR34], [@CR35]\]. Furthermore, it has been reported that tryptophan hydroxylase 1 messenger RNA, serotonin transport messenger RNA, and serotonin transport immunoreactivity all are reduced in IBS patients \[[@CR31]\]. It is possible that the observation made here on serotonin is secondary to SERT gene polymorphism and/or an altered 5-HT signaling system. It has been proposed that low-grade inflammation might be responsible for symptoms in at least a subset of IBS sufferers \[[@CR36], [@CR37]\]. It is possible that the abnormality observed here is caused by a colonic submucosal low-grade inflammation. In support of this assumption is the observation that serotonin secretion by enterochromaffin (EC) cells can be enhanced or attenuated by secretory products of immune cells, for example CD4^+^T \[[@CR38]\]. Furthermore, serotonin modulates the immune response \[[@CR38]\]. The EC cells are in contact with or very close to CD3+ and CD20+ lymphocytes and several sertotongeric receptors have been characterized in lymphocytes, monocytes, macrophages, and dendrtic cells \[[@CR38], [@CR39]\]. It has been reported that IBS-diarrhea patients have a significantly higher prevalence of macroscopic mucosal colonic erythema, with "nonspecific" inflammation being observed for a significant proportion of these patients on histopathological evaluation \[[@CR35]\]. The authors argued, however, that their findings might be explained by an ascertainment bias \[[@CR35]\]. The occurrence of colonic mucosal nonspecific inflammation in the IBS patients investigated in this study did not differ from that of healthy controls.

It is rather interesting that patients with IBS sub-types had the same abnormalities in serotonin and PYY cells. Previous studies have shown that IBS-diarrhea and IBS-constipation have the same abnormality in the serotonin signaling system \[[@CR31]\]. Actually, IBS patients are characterized basically by altered bowel habits. Dividing IBS patients into subtypes based on predominance of diarrhea or constipation is a clinical classification to facilitate clinical symptomatic management. It is possible, therefore, that IBS patients, irrespective of subtype, share the same pathophysiology.

Serotonin activates the submucosal sensory branch of the enteric nervous system and controls gastrointestinal motility and chloride secretion via interneurons and motor neurons \[[@CR40], [@CR41]\]. PYY stimulates absorption of water and electrolytes and is a major regulator of the "ileal brake" \[[@CR42]\]. Furthermore, PYY inhibits prostaglandin (PG) E2 and vasoactive intestinal peptide, which stimulate intestinal fluid secretion \[[@CR43]--[@CR45]\]. Administration of PYY inhibits diarrhea in experimental mouse models by reducing intestinal fluid secretion and slowing colonic transit \[[@CR46]\]. Although the cause and effect relationship of our findings is difficult to elucidate, the abnormalities reported here might contributes to the symptoms associated with IBS.
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